Ghezzi Pietro, Jaquet Vincent, Marcucci Fabrizio, Schmidt Harald H H W
Brighton & Sussex Medical School, Brighton, UK.
Department of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland.
Br J Pharmacol. 2017 Jun;174(12):1784-1796. doi: 10.1111/bph.13544. Epub 2016 Aug 4.
The theory that oxidative stress (OS) is at the root of several diseases is extremely popular. However, so far, no antioxidant has been recommended or offered by healthcare systems neither has any been approved as therapy by regulatory agencies that base their decisions on evidence-based medicine. This is simply because, so far, despite many preclinical and clinical studies indicating a beneficial effect of antioxidants in many disease conditions, randomised clinical trials have failed to provide the evidence of efficacy required for drug approval. In this review, we discuss the levels of evidence required to claim causality in preclinical research on OS, the weakness of the oversimplification associated with OS theory of disease and the importance of the narrative in its popularity. Finally, from a more translational perspective, we discuss the reasons why antioxidants acting by scavenging ROS might not only prevent their detrimental effects but also interfere with essential signalling roles. We propose that ROS have a complex metabolism and are generated by different enzymes at diverse sites and at different times. Aggregating this plurality of systems into a single theory of disease may not be the best way to develop new drugs, and future research may need to focus on specific oxygen-toxifying pathways rather than on non-specific ROS scavengers. Finally, similarly to what is nowadays required for clinical trials, we recommend making unpublished data available in repositories (open data), as this will allow big data approaches or meta-analyses, without the drawbacks of publication bias.
This article is part of a themed section on Redox Biology and Oxidative Stress in Health and Disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.12/issuetoc.
氧化应激(OS)是多种疾病根源的理论极为流行。然而,到目前为止,医疗保健系统既未推荐也未提供任何抗氧化剂,监管机构也未将其批准为基于循证医学做出决策的治疗方法。这仅仅是因为,到目前为止,尽管许多临床前和临床研究表明抗氧化剂在许多疾病状况下具有有益作用,但随机临床试验未能提供药物批准所需的疗效证据。在本综述中,我们讨论了在氧化应激的临床前研究中声称因果关系所需的证据水平、与疾病的氧化应激理论相关的过度简化的弱点以及该理论流行中叙述的重要性。最后,从更具转化性的角度,我们讨论了通过清除活性氧起作用的抗氧化剂不仅可能预防其有害影响,还可能干扰重要信号传导作用的原因。我们提出活性氧具有复杂的代谢过程,由不同的酶在不同的部位和不同的时间产生。将这多个系统整合到单一疾病理论中可能不是开发新药的最佳方式,未来的研究可能需要专注于特定的氧化途径而非非特异性的活性氧清除剂。最后,与如今临床试验的要求类似,我们建议将未发表的数据存于资料库(开放数据),因为这将允许采用大数据方法或进行荟萃分析,而不存在发表偏倚的弊端。
本文是关于健康与疾病中的氧化还原生物学和氧化应激主题部分的一部分。要查看本部分的其他文章,请访问http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.12/issuetoc。